Form 10-Q - Quarterly report [Sections 13 or 15(d)]

S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

PAVmed (NASDAQ:PAVM)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more PAVmed Charts.

PAVmed (NASDAQ:PAVM)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more PAVmed Charts.

PAVmed Inc News

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Monday 23 December 2024 (3 days ago) • PR Newswire (US)

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters
Thursday 19 December 2024 (7 days ago) • PR Newswire (US)

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication
Wednesday 11 December 2024 (2 weeks ago) • PR Newswire (US)

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones
Tuesday 3 December 2024 (3 weeks ago) • PR Newswire (US)

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test
Wednesday 20 November 2024 (1 month ago) • PR Newswire (US)

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Monday 18 November 2024 (1 month ago) • PR Newswire (US)

PAVmed Provides Business Update and Third Quarter 2024 Financial Results
Thursday 14 November 2024 (1 month ago) • PR Newswire (US)

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Thursday 7 November 2024 (2 months ago) • PR Newswire (US)

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers
Tuesday 5 November 2024 (2 months ago) • PR Newswire (US)

PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024
Thursday 31 October 2024 (2 months ago) • PR Newswire (US)

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024
Wednesday 30 October 2024 (2 months ago) • PR Newswire (US)

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
Tuesday 15 October 2024 (2 months ago) • PR Newswire (US)

More PAVmed Inc News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions